Omrix appoints Asaf Alperovitz CFO
This article was originally published in Scrip
Omrix Biopharmaceuticals (US), a company that develops and markets biosurgical and immunotherapy products, has appointed Asaf Alperovitz chief financial officer, effective October 23rd. Mr Alperovitz has been CFO of Tefron since 2005.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.